Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function

Journal of Neuroscience

Volumn 29, Issue 7, 2009, Pages 2238-2251

  Wallén Mackenzie, Åsa ^a   Nordenankar, Karin ^a   Fejgin, Kim ^b   Lagerström, Malin C ^a   Emilsson, Lina ^a   Fredriksson, Robert ^a   Wass, Caroline ^b   Andersson, Daniel ^b   Egecioglu, Emil ^b   Andersson, My ^b   Strandberg, Joakim ^b   Lindhe, Örjan ^c   Schiöth, Helgi B ^a   Chergui, Karima ^d   Hanse, Eric ^b   Långstrom, Bengt ^a   Fredriksson, Anders ^a   Svensson, Lennart ^b   Roman, Erika ^a   Kullander, Klas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c BIACORE AB   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Behavior; CNS; Neuronal network; Physiology; Schizophrenia; Transmitter

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMPHETAMINE; ARIPIPRAZOLE; DOPAMINE; DOPAMINE RECEPTOR; RACLOPRIDE; VESICULAR GLUTAMATE TRANSPORTER 2;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BINDING SITE; BRAIN CORTEX; BRAIN FUNCTION; BRAIN NERVE CELL; CELL SUBPOPULATION; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOWNSTREAM PROCESSING; DRUG MEGADOSE; DRUG SENSITIVITY; EMOTION; FORCED SWIMMING TEST; FOREBRAIN; GENE DELETION; HIPPOCAMPUS; LOCOMOTION; LONG TERM MEMORY; LOW DRUG DOSE; MALE; MAZE TEST; MOUSE; MUTATION; NERVE CELL NETWORK; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PREPUBERTY; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RISK ASSESSMENT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SOCIAL BEHAVIOR; SOCIAL DOMINANCE; SOCIAL INTERACTION; SPATIAL MEMORY; STARTLE REFLEX;

AGING; AMYGDALA; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CELL DIFFERENTIATION; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; HIPPOCAMPUS; MALE; MICE; MICE, KNOCKOUT; NEURAL PATHWAYS; NEURONAL PLASTICITY; NUCLEUS ACCUMBENS; SCHIZOPHRENIA; SENSORY GATING; SYNAPTIC TRANSMISSION; VESICULAR GLUTAMATE TRANSPORT PROTEIN 2;

EID: 60849088888     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5851-08.2009     Document Type: Article

References (63)

1. Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135:1081-1084.
2. Arguello PA, Gogos JA (2006) Modeling madness in mice: one piece at a time. Neuron 52:179-196.
3. Bellocchio EE, Reimer RJ, Fremeau RT Jr, Edwards RH (2000) Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289:957-960.
4. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574.
5. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molin-off PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
6. Carlsson A, Hansson LO, Waters N, Carlsson ML (1999) A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl 1999:2-6.
7. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
8. Ellenbroek BA, Sluyter F, Cools AR (2000) The role of genetic and early environmental factors in determining apomorphine susceptibility. Psy-chopharmacology(Berl) 148:124-131.
9. File SE (1980) The use of social interaction as a method for detecting anxi-olytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2:219-238.
10. Fredriksson A, Eriksson P, Archer T (1997) MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyltert-butyl-mtrone (PBN). J Neural Transm 104:579-592.
11. Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ Bellocchio EE, Fortin D, Storm-Mathisen J, Edwards RH (2001) The expression of vesicular glutamate transporters defines two classes ofexci-tatory synapse. Neuron 31:247-260.
12. Fremeau RT Jr, Voglmaier S, Seal RP, Edwards RH (2004a) VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci 27:98-103.
13. Fremeau RT Jr, Kam K, Qureshi T, Johnson J, Copenhagen DR, Storm-Mathisen J, Chaudhry FA, Nicoll RA, Edwards RH (2004b) Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304:1815-1819.
14. Gallagher M, Burwell R, Burchinal M (1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107:618-626.
15. 11C]raclo-pride displacement studies: understanding the true mechanism. Mol Imaging Biol 7:45-52.
16. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperloco-motion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
17. Gras C, Herzog E, Bellenchi GC, Bernard V, Ravassard P, Pohl M, Gasnier B, Giros B, El Mestikawy S (2002) A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci 22:5442-5451.
18. Haitina T, Takahashi A, Holmen L, Enberg J, Schioth HB (2007) Further evidence for ancient role of ACTH peptides at melanocortin (MC) receptors; pharmacology of dogfish and lamprey peptides at dogfish MC receptors. Peptides 28:798-805.
19. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, Gasnier B, Giros B, El Mestikawy S (2001) The existence of a second vesicular glu-tamate transporter specifies subpopulations of glutamatergic neurons.
20. J Neurosci 21:RC181(1-6).
21. Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR, Arber S (2005) A developmental switch in the response ofDRG neurons to ETS transcription factor signaling. PLoS Biol 3:e159.
22. Jentsch JD, Roth RH (1999) The neuropsychopharmacologyofphencyclid-ine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
23. Kaneko T, Fujiyama F (2002) Complementary distribution of vesicular glu-tamate transporters in the central nervous system. Neurosci Res 42:243-250.
24. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627-640.
25. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects ofthe noncompetitive NMDA antagonist, ketamine, in humans. Psychot-omimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51:199-214.
26. Lagerström MC, Rabe N, Haitina T, Kalnina I, Hellström AR, Klovins J, Kullander K, Schiöth HB (2007) The evolutionary history and tissue mapping of GPR123: specific CNS expression pattern predominantly in thalamic nuclei and regions containing large pyramidal cells. J Neuro-chem 100:1129-1142.
27. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol-ogy13:9-19.
28. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158.
29. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27 [Suppl A]:S16-S24.
30. Lewis DA, LiebermanJA (2000) Catching up onschizophrenia: natural his-tory and neurobiology. Neuron 28:325-334.
31. Lindblom J, Johansson A, Holmgren A, Grandin E, Nedergård C, Fredriksson R, Schiöth HB (2006) Increased mRNA levels of tyrosine hydroxylase and dopamine transporter in the VTA of male rats after chronic food restriction. Eur J Neurosci 23:180-186.
32. Lindzey G, Winston H, Manosevitz M (1961) Social dominance in inbred mouse strains. Nature 191:474-476.
33. Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, NagyA (1999) Z/AP, a double reporter for cre-mediated recombination. Dev Biol 208:281-292.
34. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363-369.
35. Meyerson BJ, Augustsson H, Berg M, Roman E (2006) The concentric square field: a multivariate test arena for analysis of explorative strategies. Behav Brain Res 168:100-113.
36. Minichiello L, Korte M, Wolfer D, Kühn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R (1999) Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24:401-414.
37. Moechars D, Weston MC, Leo S, Callaerts-Vegh Z, Goris I, Daneels G, Buist A, Cik M, van der Spek P, Kass S, Meert T, D'Hooge R, Rosenmund C, Hampson RM (2006) Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. J Neurosci 26:12055-12066.
38. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
39. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties offour NMDA receptors. Neuron 12:529-540.
40. Morris R (1984) Developments of a water-maze procedure for studying spa-tial learning in the rat. J Neurosci Methods 11:47-60.
41. Oliveira AL, Hydling F, Olsson E, Shi T, Edwards RH, Fujiyama F, Kaneko T, Hokfelt T, Cullheim S, Meister B (2003) Cellular localization of three vesicular glutamate transporter mRNAs and proteins in rat spinal cord and dorsal root ganglia. Synapse 50:117-129.
42. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation ofmGlu2/3 receptors as anew approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107.
43. Paxinos G (1994) The rat nervous system, Ed 2. San Diego: Academic.
44. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
45. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653.
46. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732.
47. Powell CM, Miyakawa T (2006) Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 59:1198-1207.
48. Roman E, Ploj K, Gustafsson L, Meyerson BJ, Nylander I (2006) Variations in opioid peptide levels during the estrous cycle in Sprague-Dawleyrats. Neuropeptides 40:195-206.
49. Sakata-Haga H, Kanemoto M, Maruyama D, Hoshi K, Mogi K, Narita M, Okado N, Ikeda Y, Nogami H, Fukui Y, Kojima I, Takeda J, Hisano S (2001) Differential localization and colocalization of two neuron-types of sodium-dependent inorganic phosphate cotransporters in rat fore-brain. Brain Res 902:143-155.
50. SeemanP, LeeT, Chau-WongM, WongK (1976) Antipsychotic drugdoses and neuroleptic/dopamine receptors. Nature 261:717-719.
51. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003) Anatomical substrates for glutamate-dopamine interactions: evidence for specificityofconnec-tions and extrasynaptic actions. Ann N Y Acad Sci 1003:36-52.
52. Smith AD, Bolam JP (1990) The neural network of the basal ganglia as re-vealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265.
53. Stornetta RL, Sevigny CP, Schreihofer AM, Rosin DL, Guyenet PG (2002) Vesicular glutamate transporter DNPI/VGLUT2 is expressed by both C1 adrenergic and nonaminergic presympathetic vasomotor neurons of the rat medulla. J Comp Neurol 444:207-220.
54. Swerdlow NR, Geyer MA (1998) Using an animal model of deficient senso-rimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301.
55. Takamori S, Rhee JS, Rosenmund C, Jahn R (2000) Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 407:189-194.
56. Takamori S, Rhee JS, Rosenmund C, Jahn R (2001) Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). J Neurosci 21:RC182(1-6).
57. TammingaCA, HolcombHH (2005) Phenotype ofschizophrenia: areview and formulation. Mol Psychiatry 10:27-39.
58. 11C-raclopride and micro PET. J Nucl Med 43:1570-1577.
59. Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, Del Rio J (2007) Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 25:281-290.
60. Tronche F, KellendonkC, Kretz O, Gass P, Anlag K, Orban PC, BockR, Klein R, SchützG (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23:99-103.
61. +/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J Neurosci 22:142-155.
62. Wallén-Mackenzie A, Gezelius H, Thoby-Brisson M, Nygård A, Enjin A, Fujiyama F, Fortin G, Kullander K (2006) Vesicular glutamate transporter 2 is required for central respiratory rhythm generation but not for locomotor central pattern generation. J Neurosci 26:12294-12307.
63. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, Brose N, Rosen-mund C (2004) An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci U S A 101:7158-7163.